Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Fulgent Genetics is a diagnostics & research business based in the US. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Fulgent Genetics employs 645 staff and has a trailing 12-month revenue of around $802.9 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $33.03 |
|---|---|
| 52-week range | $28.53 - $73.47 |
| 50-day moving average | $33.45 |
| 200-day moving average | $45.62 |
| Wall St. target price | $45.00 |
| PE ratio | 3.901 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $8.59 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $33.03 from 2023-01-25
| 1 week (2023-01-19) | 3.70% |
|---|---|
| 1 month (2022-12-23) | 8.94% |
| 3 months (2022-10-25) | -13.53% |
| 6 months (2022-07-26) | -42.76% |
| 1 year (2022-01-26) | -46.72% |
|---|---|
| 2 years (2021-01-26) | -56.32% |
| 3 years (2020-01-24) | 154.86% |
| 5 years (2018-01-26) | 537.64% |
Valuing Fulgent Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulgent Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fulgent Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Fulgent Genetics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Fulgent Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fulgent Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Fulgent Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $401.1 million.
The EBITDA is a measure of a Fulgent Genetics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $802.9 million |
|---|---|
| Operating margin TTM | 46.7% |
| Gross profit TTM | $777.1 million |
| Return on assets TTM | 17.95% |
| Return on equity TTM | 23.19% |
| Profit margin | 33.82% |
| Book value | $43.03 |
| Market capitalisation | $1 billion |
TTM: trailing 12 months
We're not expecting Fulgent Genetics to pay a dividend over the next 12 months.
Over the last 12 months, Fulgent Genetics's shares have ranged in value from as little as $28.53 up to $73.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulgent Genetics's is 1.5842. This would suggest that Fulgent Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fulgent Genetics, Inc. , together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
